|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
ocn779409545 |
| 003 |
OCoLC |
| 005 |
20241006213017.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
120306s2012 enk ob 001 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e pn
|c N$T
|d EBLCP
|d UIU
|d DG1
|d YDXCP
|d CDX
|d MYG
|d OCLCQ
|d OCLCF
|d OCLCQ
|d COO
|d OCLCQ
|d DG1
|d LIP
|d ZCU
|d MERUC
|d OCLCQ
|d NJR
|d U3W
|d OCLCQ
|d COCUF
|d ICG
|d AU@
|d OCLCQ
|d DKC
|d OCLCQ
|d EZ9
|d TUHNV
|d OCLCO
|d OCLCA
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCA
|d OCLCQ
|d OCLCL
|
| 019 |
|
|
|a 1190695096
|a 1193554648
|
| 020 |
|
|
|a 9781118230275
|q (electronic bk.)
|
| 020 |
|
|
|a 1118230272
|q (electronic bk.)
|
| 020 |
|
|
|a 9781118230251
|q (electronic bk.)
|
| 020 |
|
|
|a 1118230256
|q (electronic bk.)
|
| 020 |
|
|
|a 9781280588532
|
| 020 |
|
|
|a 1280588535
|
| 020 |
|
|
|z 9780470170830
|
| 020 |
|
|
|z 0470170832
|
| 035 |
|
|
|a (OCoLC)779409545
|z (OCoLC)1190695096
|z (OCoLC)1193554648
|
| 037 |
|
|
|a 361836
|b MIL
|
| 050 |
|
4 |
|a R853.B54
|b P74 2012eb
|
| 072 |
|
7 |
|a MED
|x 023000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 058170
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 072000
|2 bisacsh
|
| 072 |
|
7 |
|a KNDP
|2 bicssc
|
| 072 |
|
7 |
|a MJ
|2 bicssc
|
| 072 |
|
7 |
|a MM
|2 bicssc
|
| 072 |
|
7 |
|a MMG
|2 bicssc
|
| 072 |
|
7 |
|a PN
|2 bicssc
|
| 072 |
|
7 |
|a TDCW
|2 bicssc
|
| 049 |
|
|
|a HCDD
|
| 245 |
0 |
0 |
|a Predictive approaches in drug discovery and development :
|b biomarkers and in vitro/in vivo correlations /
|c edited by J. Andrew Williams [and others].
|
| 260 |
|
|
|a Oxford :
|b Wiley-Blackwell,
|c 2012.
|
| 300 |
|
|
|a 1 online resource (xvii, 387 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Wiley series on technologies for the pharmaceutical industry.
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a The importance of biomarkers in translational medicine / Joseph Fleishaker -- Fit for purpose validation of biochemical assays : challenges and solutions / Gabriella Szekely-Klepser and Scott Fountain -- Transcriptional profiling in biomarker discovery / Michael E. Burczynski [and others] -- Proteomic biomarker approaches in drug discovery and development / Ruth A. Vanbogelen, Jeffrey D. Thomas, and Diane Alessi -- Application of metabolomics to pharmaceutical research and development / Qiuwei Xu and William H. Schaefer -- Vascular biomarkers and imaging studies / Karin Potthoff, Ulrike Fiedler, and Joachim Drevs -- Cardiovascular biomarkers as examples of success and failure in predicting safety in humans / Simon Authier [and others] -- Use of molecular imaging for receptor occupancy decision making in drug development / R. Paul Maguire -- Biosensors for clinical biomarkers / Sara Tombelli and Marco Mascini -- US regulatory perspective on biomarker development / Rajnikath Madabushi, Lawrence Lesko, and Janet Woodcock -- EU regulatory perspective on biomarkers / Ian Hudson -- Use of biomarkers in drug development : Japanese perspectives / Yoshiaki Uyama [and others] -- In vitro-in vivo correlations of hepatic drug clearance / R. Scott Obach -- The potential of in silico and in vitro approaches to predict in vivo drug-drug interactions and ADMET/TOX properties / Kenneth Bachmann and Sean Ekins -- In vitro-in vivo correlations in drug discovery and development : concepts and applications in toxicology / Rex Denton, Kimberly Brannen, and Buce D. Car -- Assessing the potential for induction of cytochrome P450 enzymes and predicting the in vivo response / Jiunn H. Lin.
|
| 520 |
|
|
|a Practical Utility of Biomarkers in Drug Discovery and Development covers all aspects of biomarker research applied to drug discovery and development and contains state-of-the-art appraisals on the practical utility of genomic, biochemical, and protein biomarkers. Case histories and lessons from successful and unsuccessful applications of biomarkers are included along with key chapters on GLP validation, safety biomarkers and proteomics biomarkers. Regulatory agency perspectives and initiatives both in the US and internationally are also discussed.
|
| 650 |
|
0 |
|a Biochemical markers.
|
| 650 |
|
0 |
|a Drug development.
|
| 650 |
|
0 |
|a Pharmaceutical technology.
|
| 650 |
|
7 |
|a MEDICAL
|x Drug Guides.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Nursing
|x Pharmacology.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Pharmacology.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Pharmacy.
|2 bisacsh
|
| 650 |
|
7 |
|a Biochemical markers
|2 fast
|
| 650 |
|
7 |
|a Drug development
|2 fast
|
| 650 |
|
7 |
|a Pharmaceutical technology
|2 fast
|
| 700 |
1 |
|
|a Williams, J. Andrew.
|
| 758 |
|
|
|i has work:
|a Predictive approaches in drug discovery and development (Text)
|1 https://id.oclc.org/worldcat/entity/E39PCGcFpYyQyDRBbgBmYGgMyd
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
| 776 |
0 |
8 |
|i Print version:
|t Predictive approaches in drug discovery and development.
|d Oxford : Wiley-Blackwell, 2012
|z 9780470170830
|w (OCoLC)775028111
|
| 830 |
|
0 |
|a Wiley series on technologies for the pharmaceutical industry.
|
| 856 |
4 |
0 |
|u https://ebookcentral.proquest.com/lib/holycrosscollege-ebooks/detail.action?docID=822092
|y Click for online access
|
| 903 |
|
|
|a EBC-AC
|
| 994 |
|
|
|a 92
|b HCD
|